The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients.

Abstract

BACKGROUND: Fibroblast growth factor receptor 4 (FGFR4) was seldom investigated in gastric cancer (GC). The purpose of the study was to elucidate the expression of FGFR4 protein in GC and related clinical significance. METHODS: Ninety-four paraffin-embedded tumor specimens were obtained from Cancer Hospital, Fudan University. The expression of FGFR4 as well as p53, p21, EGFR, neu, c-myc, and PCNA were detected by immunohistochemical method. Then, correlation analysis and survival analysis were performed. RESULTS: The expression rate of FGFR4 protein in GC tissues and normal stomach tissues was 93.6% and 30.8%, respectively (P = 0.000). The expression of FGFR4 was positively correlated with the expression of p21, neu and PCNA (P-value was 0.009, 0.012, and 0.018, respectively). Subgroup analysis showed that compared to low expression group, the prognosis of patients with III/IV stage and negative expression of p21 in high expression group of FGFR4 were worse (P = 0.048, 0.041, respectively). Multivariate analysis showed that TNM stage was the independent prognostic factor in high expression group (HR, 11.593; 95% CI, 3.532-18.058; P = 0.000). CONCLUSIONS: High expression of FGFR4 protein, accelerating the progression of advanced GC, might be associated with a poor prognosis in patients with advanced FC. J. Surg. Oncol © 2012 Wiley Periodicals, Inc.